Biomednewsbreaks - Aditxt Inc. (NASDAQ: ADTX) Releases Report On Annual Shareholders' Meeting Activity

(MENAFN- Investor Brand Network) Aditxt
(NASDAQ: ADTX) , an innovation platform dedicated to discovering, developing and deploying promising innovations, is reporting on the results of its recent annual shareholders' meeting. According to the announcement, all nine proposed agenda items were successfully passed. Those proposals include the election of directors, the ratification of auditors, and the issuing of shares for Series B-1 and B-2 convertible preferred stock addition, a proposed Equity Line of Credit (ELOC) and share increase
was approved, among other items.

“I want to thank all of our stakeholders for their participation and continued support,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release.“We believe that the approval of these proposals will equip us with important tools as we continue to work on meeting certain of our existing obligations and position Aditxt towards achieving our strategic initiatives.”

To view the full press release, visit

About Aditxt Inc.

Aditxt is an innovation platform dedicated to discovering, developing and deploying promising innovations. Aditxt's ecosystem of research institutions, industry partners and shareholders collaboratively drive its mission to“Make Promising Innovations Possible Together.” The innovation platform is the cornerstone of Aditxt's strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder's voice is heard and valued, and empowers collective progress. Aditxt has a diverse innovation portfolio, which includes the following: Adimune(TM) Inc., which is leading the charge in developing a novel class of therapeutics for retraining the immune system to combat organ rejection, autoimmunity and allergies; Adivir(TM) Inc., which focuses on enhancing national and population health and impacting public health globally; and Pearsanta(TM) Inc., which delivers rapid, personalized and high-quality lab testing accessible anytime, anywhere, led by its CLIA-certified and CAP-accredited clinical laboratory based in Richmond, Virginia. For more information, please visit .

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by
IBN

MENAFN13082024000224011066ID1108550352